Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protexin Restore is a multi-strain synbiotic developed by Protexin Healthcare (a brand of ADM Protexin Limited). It is a live biotherapeutic product consisting of a mixture of seven probiotic bacterial strains—*Lactobacillus casei*, *Lactobacillus rhamnosus*, *Streptococcus thermophilus*, *Bifidobacterium breve*, *Lactobacillus acidophilus*, *Bifidobacterium infantis*, and *Lactobacillus bulgaricus*—combined with the prebiotic fructooligosaccharide (FOS). The product is designed to modulate the gut microbiota and restore healthy intestinal flora, particularly in infants and young children. Clinical studies have demonstrated its efficacy in reducing the severity of atopic dermatitis (AD), as measured by the SCORAD index, and it has also been investigated for its impact on anthropometric measurements and microbiota composition in pediatric obesity (Probesity-2 trial). It is typically administered as an oral freeze-dried powder.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Protexin Restore.